RVPH Key Statistics, Chart & Performance
The current stock price of RVPH is 0.278 USD. In the past month the price decreased by -45.1%. In the past year, price decreased by -84.56%.
RVPH Latest News, Press Relases and Analysis
RVPH Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 48.98 | 1.02T | ||
| JNJ | JOHNSON & JOHNSON | 20.02 | 500.60B | ||
| MRK | MERCK & CO. INC. | 12.08 | 264.21B | ||
| PFE | PFIZER INC | 7.82 | 142.31B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.34 | 111.38B | ||
| ZTS | ZOETIS INC | 19.79 | 55.30B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.55 | 22.66B | ||
| VTRS | VIATRIS INC | 5.25 | 14.10B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.31 | 11.12B | ||
| CORT | CORCEPT THERAPEUTICS INC | 94.99 | 8.79B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.74B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.41B |
Related stock screener links
About RVPH
Company Profile
Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutics for the central nervous system, respiratory, and metabolic diseases. The company is headquartered in Cupertino, California and currently employs 14 full-time employees. The company went IPO on 2018-10-18. The firm discovers, develops, and seeks to commercialize therapeutics for diseases representing unmet medical needs. The Company’s pipeline focuses on the central nervous system, inflammatory, and cardiometabolic diseases. Its pipeline includes two drug candidates, brilaroxazine (RP5063) and RP1208. Its lead drug candidate, brilaroxazine, is in clinical development and is to treat multiple neuropsychiatric indications. These include schizophrenia, bipolar disorder (BD), major depressive disorder (MDD), attention-deficit/hyperactivity disorder (ADHD), behavioral and psychotic symptoms of dementia or Alzheimer’s disease (BPSD), and Parkinson’s disease psychosis. Brilaroxazine is also ready for clinical development for two respiratory indications, including pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF). Its RP1208 drug candidate is a triple reuptake inhibitor (TRI).
Company Info
REVIVA PHARMACEUTICALS HOLDI
10080 N Wolfe Road, Suite Sw3-200
Cupertino CALIFORNIA 95014 US
CEO: Laxminarayan Bhat
Employees: 14
Phone: 14085018881
REVIVA PHARMACEUTICALS HOLDI / RVPH FAQ
Can you describe the business of REVIVA PHARMACEUTICALS HOLDI?
Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutics for the central nervous system, respiratory, and metabolic diseases. The company is headquartered in Cupertino, California and currently employs 14 full-time employees. The company went IPO on 2018-10-18. The firm discovers, develops, and seeks to commercialize therapeutics for diseases representing unmet medical needs. The Company’s pipeline focuses on the central nervous system, inflammatory, and cardiometabolic diseases. Its pipeline includes two drug candidates, brilaroxazine (RP5063) and RP1208. Its lead drug candidate, brilaroxazine, is in clinical development and is to treat multiple neuropsychiatric indications. These include schizophrenia, bipolar disorder (BD), major depressive disorder (MDD), attention-deficit/hyperactivity disorder (ADHD), behavioral and psychotic symptoms of dementia or Alzheimer’s disease (BPSD), and Parkinson’s disease psychosis. Brilaroxazine is also ready for clinical development for two respiratory indications, including pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF). Its RP1208 drug candidate is a triple reuptake inhibitor (TRI).
Can you provide the latest stock price for REVIVA PHARMACEUTICALS HOLDI?
The current stock price of RVPH is 0.278 USD. The price decreased by -13.48% in the last trading session.
Does REVIVA PHARMACEUTICALS HOLDI pay dividends?
RVPH does not pay a dividend.
How is the ChartMill rating for REVIVA PHARMACEUTICALS HOLDI?
RVPH has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Is REVIVA PHARMACEUTICALS HOLDI (RVPH) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on RVPH.
What is the market capitalization of RVPH stock?
REVIVA PHARMACEUTICALS HOLDI (RVPH) has a market capitalization of 31.99M USD. This makes RVPH a Nano Cap stock.
RVPH Technical Analysis
RVPH Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to RVPH. RVPH scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
RVPH Financial Highlights
Over the last trailing twelve months RVPH reported a non-GAAP Earnings per Share(EPS) of -0.46. The EPS increased by 58.56% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -158.77% | ||
| ROE | -500.18% | ||
| Debt/Equity | 0 |